Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus
Abstract Background Effective antiviral therapy is lacking for most viral infections, and when available, is frequently compromised by the selection of resistance. Targeted protein degraders could provide an avenue to more effective antivirals, able to overcome the selection of resistance. The aim o...
Saved in:
| Main Authors: | Baolong Pan, Simon J. Mountford, Maki Kiso, Danielle E. Anderson, Georgina Papadakis, Kate E. Jarman, Danielle R. Tilmanis, Belinda Maher, Thomas Tran, Jake Shortt, Seiya Yamayoshi, Yoshihiro Kawaoka, Philip E. Thompson, Sam A. Greenall, Nadia Warner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-025-00863-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of baloxavir marboxil against bovine H5N1 virus in mice
by: Maki Kiso, et al.
Published: (2025-06-01) -
An Investigation of Nirmatrelvir (Paxlovid) Resistance in SARS-CoV‑2 Mpro
by: Rasha M. Yaghi, et al.
Published: (2024-10-01) -
An XBB.1.5-based inactivated SARS-CoV-2 vaccine partially protects against XBB.1.5 and JN.1 strains in hamsters
by: Ryuta Uraki, et al.
Published: (2025-02-01) -
An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variantResearch in context
by: Ryuta Uraki, et al.
Published: (2025-07-01) -
Development of a highly sensitive luciferase assay for intracellular evaluation of coronavirus Mpro activity
by: Bao Dong, et al.
Published: (2025-04-01)